FDA Approves Oral Suspension for Gastric Ulcers
Konvomep, an oral liquid of omeprazole and sodium bicarbonate, will be available in the first quarter of 2023
The FDA has approved Azurity Pharmaceuticals’ Konvomep (omeprazole and sodium bicarbonate). Konvomep is an oral suspension to treat active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.
Azurity officials expect Konvomep will become commercially available in the first quarter of 2023.
Olga Hilas, Pharm.D.
“Patients who struggle with taking solid oral dosage forms may be overlooked and have historically had limited FDA-approved treatment options available as liquid formulations,” Olga Hilas, Pharm.D., MPH, professor, clinical health professions at St. John’s University College of Pharmacy & Health Sciences, Queens, New York, said in a press release.
In July 2022, the FDA approved Azurity’s Zonisade, an oral suspension of zonisamide to treat partial seizures in adults and pediatric patients aged 16 years and older with epilepsy. This is the first oral liquid form of zonisamide.
Zonisade was developed by Eton Pharmaceuticals, and was one of three drugs sold to Azurity in February 2021. The other two therapies include lamotrigine and topiramate. Topiramate was approved by the FDA in November 2021 with the brand name of Eprontia.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
